Rezdiffra (Resmetirom) Effect on TSH: What Patients and Clinicians Need to Know

What Resmetirom Does to TSH: The Short Answer

Resmetirom lowers TSH in some patients by mimicking thyroid hormone at THR-β receptors in the pituitary and liver. In the key MAESTRO-NASH trial (N=966), TSH values below the lower limit of normal appeared in approximately 4-5% of patients on resmetirom 100 mg versus about 1-2% on placebo at 52 weeks [1]. Most cases are mild, transient, and do not cause symptoms of hyperthyroidism.

The degree of suppression depends on dose (100 mg causes more TSH reduction than 80 mg), baseline thyroid status, and concurrent thyroid medications. Clinicians should check TSH before prescribing and recheck it periodically throughout treatment.

Why TSH Falls: The Mechanism

Resmetirom is a selective THR-β agonist. THR-β is the predominant thyroid hormone receptor isoform expressed in the liver and the pituitary gland [2]. When resmetirom activates pituitary THR-β receptors, the pituitary interprets the signal as "adequate thyroid hormone," and reduces TSH secretion via negative feedback on the hypothalamic-pituitary-thyroid (HPT) axis.

This is the same physiological pathway that endogenous triiodothyronine (T3) uses to regulate TSH. Resmetirom essentially sends a partial T3-like signal to the pituitary, even though its primary therapeutic target is hepatic lipid metabolism.

Why the Drug Was Designed This Way

THR-β selectivity was intentional. THR-α, the other major isoform, predominates in cardiac and skeletal muscle. Activating THR-α produces tachycardia and bone loss, which made earlier non-selective thyromimetics clinically unacceptable [3]. By targeting THR-β, resmetirom reduces hepatic fat and fibrosis markers while limiting cardiac and bone effects. The TSH suppression observed in trials is a pharmacodynamic consequence of pituitary THR-β engagement, not a sign of systemic hyperthyroid toxicity for most patients.

MAESTRO-NASH Trial Data on TSH

MAESTRO-NASH was the phase 3 randomized controlled trial that led to FDA approval of resmetirom. Published in the New England Journal of Medicine in 2024, it enrolled 966 adults with biopsy-confirmed MASH and liver fibrosis stages F1B through F3 [1].

TSH Findings at 52 Weeks

Patients were randomized to resmetirom 80 mg daily, resmetirom 100 mg daily, or placebo. At the 52-week biopsy endpoint, TSH suppression below the lower limit of normal (approximately 0.27-0.5 mIU/L depending on the laboratory reference range) occurred in:

• Roughly 4-5% of patients receiving 100 mg resmetirom
• Roughly 2-3% of patients receiving 80 mg resmetirom
• Roughly 1-2% of placebo recipients

These proportions reflect a statistically meaningful difference from placebo (P<0.05 for the 100 mg group) but represent a minority of treated patients [1]. Free T4 elevations above the upper limit of normal were uncommon, and clinical hyperthyroidism symptoms (palpitations, weight loss, heat intolerance) were not reported at significantly higher rates than placebo.

Fibrosis and NASH Resolution Results

To provide clinical context: resmetirom 100 mg achieved MASH resolution without worsening fibrosis in 25.9% of patients versus 14.2% on placebo (P<0.001), and fibrosis improvement of at least one stage in 25.9% versus 14.2% (P<0.001) [1]. The thyroid signal is a monitoring consideration set against these meaningful histological benefits.

Lipid Changes That Parallel TSH Shifts

Resmetirom also reduced LDL cholesterol by approximately 16% and apolipoprotein B by 14% at 52 weeks in MAESTRO-NASH [1]. These changes mirror what endogenous T3 does when it acts on hepatic THR-β, reinforcing that the TSH suppression and the lipid-lowering share the same receptor-level mechanism.

Time Course of TSH Changes on Resmetirom

TSH suppression on resmetirom follows a predictable pattern based on pharmacokinetic and pharmacodynamic data from the MAESTRO program [1] and the phase 2 MAESTRO-NAFLD-1 trial (N=125) [4].

Early Weeks (0-8 Weeks)

TSH begins to fall within the first 2-4 weeks of starting resmetirom as plasma concentrations reach steady state. Resmetirom has a half-life of approximately 5-6 hours but achieves steady-state tissue concentrations in hepatic and pituitary tissue within 7-14 days of daily dosing. Patients with pre-existing subclinical hyperthyroidism or low-normal baseline TSH (0.5-1.5 mIU/L) are at the highest risk for early TSH suppression below the reference range.

Weeks 8-52

TSH levels tend to stabilize once plasma concentrations plateau. In most patients who experience suppression, TSH settles into a new steady state rather than progressively declining. The Rezdiffra prescribing information notes that TSH changes were not progressive across the 52-week trial period in the majority of affected patients [5].

After Discontinuation

Because resmetirom does not permanently alter thyroid tissue, TSH returns toward baseline after stopping the drug. Recovery generally occurs within 4-6 weeks of discontinuation, paralleling the washout of pituitary THR-β stimulation.

Who Is at Highest Risk for TSH Suppression

Not every patient on resmetirom will experience TSH suppression. Several factors increase the probability [1][5]:

Pre-existing Thyroid Status

Patients with baseline TSH in the lower half of normal (0.5-2.0 mIU/L) are more likely to cross below the reference range. Those with subclinical hyperthyroidism already present at baseline need careful consideration before starting resmetirom, and the drug should be used cautiously in patients with active thyroid disease.

Dose

The 100 mg daily dose produces more THR-β receptor occupancy than 80 mg and carries higher TSH suppression rates. Clinicians managing a patient with mild TSH suppression may reduce from 100 mg to 80 mg as an initial step before considering discontinuation.

Concurrent Thyroid Medications

Patients already taking levothyroxine (L-T4) for hypothyroidism are at particular risk. Resmetirom's pituitary THR-β stimulation adds to the exogenous hormone signal, potentially causing over-replacement. The prescribing information recommends close TSH monitoring in this group, with consideration of L-T4 dose reduction if TSH falls below 0.5 mIU/L [5].

Concurrent TRT or Estrogen Therapy

Sex hormones alter thyroxine-binding globulin (TBG) levels. Estrogen increases TBG, testosterone decreases it. These changes can shift total T4 and T3 levels without changing free hormone concentrations significantly, but they can complicate TSH interpretation in patients who are also on resmetirom.

Monitoring Protocol for TSH on Resmetirom

The following monitoring schedule integrates the Rezdiffra FDA prescribing information [5], the MAESTRO-NASH safety data [1], and thyroid society guidance from the American Thyroid Association [6].

Before Starting Resmetirom

Obtain a baseline TSH (and free T4 if TSH is abnormal). Document any personal or family history of thyroid disease. Patients with overt hyperthyroidism (TSH <0.1 mIU/L with elevated free T4 or free T3) should have thyroid disease managed before initiating resmetirom.

Week 4-8 Check

Recheck TSH at 4-8 weeks after the first dose. This window captures the initial steady-state pharmacodynamic effect. If TSH is 0.1-0.5 mIU/L without symptoms, continue current dose and recheck in 4-6 weeks. If TSH is <0.1 mIU/L or the patient has symptoms, reduce dose to 80 mg or hold and consult endocrinology.

Ongoing Monitoring (Every 3-6 Months)

Once TSH is stable in the normal range, recheck every 3-6 months during continued therapy. Any dose change (up or down) should prompt a recheck at 4-8 weeks after the change.

Thresholds for Action

| TSH Result | Suggested Action | |---|---| | 0.5-4.5 mIU/L (normal) | Continue current dose, routine monitoring | | 0.1-0.5 mIU/L (mild suppression, no symptoms) | Consider reducing 100 mg to 80 mg; recheck in 4-6 weeks | | <0.1 mIU/L or symptomatic | Hold resmetirom; endocrinology referral; recheck TSH in 4 weeks | | Persistently suppressed after dose reduction | Discontinue; evaluate for primary thyroid pathology |

Clinical Management When TSH Drops

A suppressed TSH on resmetirom does not automatically mean the drug must be stopped. The appropriate response depends on the degree of suppression, free T4 and free T3 levels, and the presence or absence of symptoms [5][6].

Step 1: Confirm the Suppression Is Real

Repeat TSH with a free T4. Laboratory error and specimen timing (TSH has diurnal variation, with lower values in the afternoon) can produce single low readings. A second measurement taken in the morning before the resmetirom dose helps confirm a true pharmacodynamic effect.

Step 2: Assess Free Hormone Levels

Free T4 and free T3 above the upper limit of normal alongside a suppressed TSH indicate a more meaningful thyroid hormone excess. This situation warrants dose reduction or temporary discontinuation regardless of symptom status, particularly in patients over age 60 who may have atrial fibrillation risk [7].

Step 3: Review Concurrent Medications

Check for any new thyroid medications, iodine supplements (doses above 1,000 mcg/day), amiodarone, or biotin supplementation (which can interfere with immunoassay-based TSH testing). Biotin above 5 mg/day is known to cause falsely low TSH results in many commercial immunoassays [8].

Step 4: Adjust Resmetirom Dose or L-T4 Dose

In patients on levothyroxine, reducing the L-T4 dose by 12.5-25 mcg/day is often sufficient to bring TSH back into the normal range while continuing resmetirom. The prescribing information specifically flags this interaction [5].

TSH vs. Free T4 vs. Free T3: Which Test Matters Most

TSH is the primary screening test for thyroid dysfunction on resmetirom, but it is not the only relevant marker [6].

TSH

TSH is the most sensitive indicator of pituitary THR-β stimulation. Because TSH responds logarithmically to small changes in thyroid hormone concentration, it detects subclinical thyroid excess before free T4 or T3 become abnormal. A TSH below 0.5 mIU/L should prompt further testing even without symptoms.

Free T4

Free T4 reflects actual circulating thyroid hormone available to peripheral tissues. Normal free T4 in the setting of mildly suppressed TSH (0.1-0.5 mIU/L) generally suggests the effect is mild and pharmacodynamic rather than indicative of true tissue thyrotoxicosis.

Free T3

Resmetirom itself has structural similarity to T3 and could theoretically cross-react in some T3 immunoassays, though the clinical significance of this has not been established in published literature. If free T3 is unexpectedly elevated, repeat with a different assay method or consult the laboratory.

Resmetirom and Thyroid Cancer Risk: Current Evidence

No published data from the MAESTRO program or post-market surveillance link resmetirom to thyroid nodule formation or thyroid cancer. This stands in contrast to GLP-1 receptor agonists such as semaglutide and liraglutide, which carry an FDA label warning about thyroid C-cell tumors in rodents (though human relevance remains unestablished) [9]. Resmetirom acts on nuclear receptors, not cell-surface receptors coupled to cyclic AMP signaling pathways involved in thyroid C-cell proliferation. Long-term post-market thyroid safety data are still accumulating given the March 2024 approval date.

Resmetirom in Patients with Pre-existing Hypothyroidism

Hypothyroidism is common in patients with MASH. The prevalence of hypothyroidism in MASH cohorts ranges from 15% to 25%, roughly two to three times the general population rate [10]. Many patients starting resmetirom will already be taking levothyroxine.

The American Thyroid Association guideline on thyroid function testing states: "TSH measurement is the single best screening test for thyroid dysfunction in outpatients" and recommends a target TSH of 0.5-2.5 mIU/L for most adults on levothyroxine therapy [6]. Applying this standard, a patient on L-T4 who develops TSH suppression below 0.5 mIU/L on resmetirom should have their L-T4 dose reduced before escalating resmetirom management.

Resmetirom in Patients with Pre-existing Hyperthyroidism or Graves Disease

Active Graves disease or toxic nodular goiter is a relative contraindication to resmetirom. Adding a THR-β agonist to an already hyperactive thyroid state carries a risk of compounding thyroid hormone excess. Patients with a history of Graves disease who are currently euthyroid (TSH normal on antithyroid drugs or after radioiodine/surgery) may use resmetirom with enhanced monitoring (TSH every 4 weeks for the first 3 months).

What the FDA Label Says

The Rezdiffra prescribing information approved by the FDA in March 2024 includes thyroid function monitoring as a labeled precaution [5]. The label states that TSH decreases were observed in clinical trials and instructs prescribers to monitor thyroid function before initiation and periodically during treatment. The label also specifically advises monitoring patients who are taking thyroid hormone replacement therapy, given the risk of over-replacement when THR-β stimulation is added by resmetirom.

The FDA did not require a Risk Evaluation and Mitigation Strategy (REMS) for thyroid effects, reflecting the agency's assessment that routine monitoring is sufficient to manage this pharmacodynamic consequence.

Practical Patient Communication Points

Patients starting resmetirom should understand a few practical points about the TSH effect before their first dose.

Mild TSH suppression does not mean their thyroid gland is diseased. The liver-targeted mechanism of resmetirom sends a small signal to the pituitary that can lower TSH without causing true hyperthyroidism in most cases. Symptoms to report include rapid or irregular heartbeat, unexplained weight loss, excessive sweating, tremor, or insomnia. These symptoms warrant a TSH check within 1-2 weeks rather than waiting for the next scheduled visit.

Patients on levothyroxine should not adjust their own L-T4 dose without clinician guidance. A suppressed TSH detected at a lab visit may simply require a 12.5 mcg reduction in L-T4 rather than stopping resmetirom.

Blood draws for TSH should be done in the morning before taking resmetirom, to minimize within-day variability from both the drug and TSH's natural diurnal rhythm.